高级检索
当前位置: 首页 > 详情页

The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects

文献详情

编号/登记号:
注册时间:
研究开始时间:
研究结束时间:
项目类型:
本院角色:
多中心研究:
招募状态:
试验分期:
研究疾病/适应症:
研究类型:
研究负责人:
研究单位: [1]Cancer Institute and Hospital, Chinese Academy of Medical Sciences [2]NanJing PLA 81 Hospital [3]Beijing Shenogen Biomedical Co., Ltd [4]Eastern Theater General Hospital,QinHuai District Medical Area [5]Peking University Cancer Hospital & Institute [6]Chinese PLA General Hospital [7]Beijing Hospital [8]General Hospital of Chinese Armed Police Forces [9]Guang'anmen Hospital of China Academy of Chinese Medical Sciences [10]Jinan Central Hospital [11]Linyi Cancer Hospital [12]The First Affiliated Hospital of Anhui Medical University [13]Anhui Provincial Hospital [14]The First Affiliated Hospital with Nanjing Medical University [15]The Affiliated Tumor Hospital of Nantong University, Nantong, Jiangsu Province, China [16]Nanfang Hospital of Southern Medical University [17]First People's Hospital of Foshan [18]Affiliated Cancer Hospital & Institute of Guangzhou Medical University [19]Tianjin Medical University Cancer Institute and Hospital [20]The Fourth Hospital of Hebei Medical University [21]Hunan Cancer Hospital [22]The First Hospital of Jilin University [23]307 Hospital of PLA [24]Fudan University [25]Henan Cancer Hospital [26]Jilin Provincial Tumor Hospital [27]First Affiliated Hospital of Harbin Medical University [28]First Affiliated Hospital Bengbu Medical College [29]The First Affiliated Hospital of Soochow University [30]Tongji Hospital [31]Beijing YouAn Hospital

研究目的:
The primary efficacy index of this study is to compare the OS of the two groups.

资源点击量:434 今日访问量:0 总访问量:419 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)